Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

mor masses is a major unmet need in a wide range of settings. It is our belief that, as a result, this technology has the potential to provide a broadly active new modality to substantially improve patient outcomes in a variety of hard-to-treat tumor types. "

Phase III Study Design

The Phase III study design agreed with the FDA follows directly from the design of the previous study. The Phase III study will also enroll previously untreated patients with locally advanced disease. The primary objective of the study will be to demonstrate a statistically significant increase in 2-year event free survival (i.e. relapse, progression, or death) for patients treated with chemoradiation together with OncoVEX (GM-CSF) as compared to patients treated with chemoradiation alone. The study will involve approximately 400 patients with approximately 200 in each arm.

Phase I/II Study Design and Results

In a Phase I/II study, OncoVEX (GM-CSF) was administered by direct injection, at three dose levels, into tumor containing lymph nodes in combination with standard first line chemo radiotherapy every three weeks for four cycles. All patients then went for surgery. Of the 17 patients enrolled, 16 had Stage IV N2 or N3 disease. OncoVEX (GM-CSF) was shown to be well tolerated with no significant side effects in addition to those associated with chemoradiation. With respect to efficacy, 93% of patients had a complete pathological response at surgery, with five patients achieving a complete response after only 2 or 3 virus doses. No patient to date has had a loco-regional recurrence in the neck at a median follow up of 30 months, and the disease specific survival rate is currently 82%.

Dr Robert Coffin, Founder and Chief Technology Officer, for BioVex, said:

"Loco-regional control is extremely important in head and neck cancer where loco regional progr
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... SHANGHAI , May 6, 2015 Dr ... institute of Massey University, will deliver a speech at the ... 24-25 at the Shanghai New Expo Center.  ... he will introduce to attendees the topic: ,Potato Starch: ... Bulk-ingredients and Smart Foods., Co-editor of a ...
(Date:5/5/2015)... DIEGO AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose Biosciences ... today reported financial results for the three months ended ... specified otherwise, all amounts are in Canadian dollars. ... its fiscal year end from May 31 to December ... interim period being reported is for the three months ...
(Date:5/5/2015)... Mich. (PRWEB) May 05, 2015 ... publishing services to develop custom course materials for smaller ... annual enrollments as low as 200 students. , ... a broader range of higher education instructors,” said Jeff ... the country, we can do our part to make ...
(Date:5/5/2015)... May 05, 2015 The Academy of ... of Indiana, led by Indiana Gov. Mike Pence, has ... AMA Foundation will host a Family Fest and aviation ... proceeds will benefit the Wounded Warrior Project. , National ... of Model Aeronautics—the country’s foremost organization for model aviation—to ...
Breaking Biology Technology:Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2State of Indiana proclaims August 15 as Model Aviation Day 2
... testing market is projected to grow at a healthy pace to ... growing incidence of genetic diseases and growing consumer awareness and rising ... ... (PRWEB) October 30, 2008 -- Genetic testing, which of-late has been ...
... at the National Institute of Standards and ... microscope to quickly and cheaply analyze nanoscale ... Scanning Optical Microscope (TSOM) imaging, the technique ... control and biotechnology. , Optical microscopes are ...
... PALO ALTO, Calif., Oct. 29 Telik, Inc.,(Nasdaq: ... an interrupted Phase 3,randomized study of Telcyta (canfosfamide ... PLD alone in second-line,therapy in platinum refractory, primary ... of platinum status are,provided below)., On an ...
Cached Biology Technology:Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3Nanoscale dimensioning is fast, cheap with new NIST optical technique 2Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 2Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 3Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 4
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... forever change the way some of the most widely used ... Science , he and his partner in the research, ... a reality. The discovery appears in the October 28, 2011 ... synthesis of homogeneous ultra-low molecular weight heparins." Linhardt, the ...
... Naval Research (ONR) will promote its science and technology ... (HACU) 25th Annual Conference, Oct. 29-31, in San Antonio. ... the Department of the Navy,s (DoN) science and technology ... funding, internship and fellowship opportunities. It is aimed at ...
... how mice recover after H1N1 flu, researchers at Harvard Medical ... A*STAR of Singapore, have cloned three distinct stem cells from ... can form into the lung,s alveoli air sac tissue. What,s ... are rapidly deployed in a dynamic process of lung regeneration ...
Cached Biology News:Discovery announced in Science represents 'new paradigm' in the way drugs can be manufactured 2Discovery announced in Science represents 'new paradigm' in the way drugs can be manufactured 3Lung stem cells offer therapeutic clues 2
...
... PI is used in conjuction with Annexin ... the earlier stages of apoptosis (Annexin V ... in later stages of apoptosis or already ... is detected in the orange range of ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... a software package that provides crystallographers ... custom buffer creation, set-up of experimental ... trials. The software helps crystallographers through ... protein crystallography: Design ...
Biology Products: